| Ronald S Kent, MD | |
|
1112 Walden Way, Hattiesburg, MS 39402-7056 | |
| (601) 310-9811 | |
| (601) 310-9811 |
| Full Name | Ronald S Kent |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 1112 Walden Way, Hattiesburg, Mississippi |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417061250 | NPI | - | NPPES |
| 1559008 | Other | MS | AMERICAN ADMIN GROUP |
| 00115703 | Medicaid | MS | |
| 1973297 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 08370 (Mississippi) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ronald S Kent, MD 1112 Walden Way, Hattiesburg, MS 39402-7056 Ph: (601) 310-9811 | Ronald S Kent, MD 1112 Walden Way, Hattiesburg, MS 39402-7056 Ph: (601) 310-9811 |
News Archive
Work hour restrictions for resident physicians, revised nationally four years ago largely to protect patients against physician trainees' fatigue-related errors, have not had the desired effect of lowering postoperative complication rates in several common surgical specialties, according to new study results.
A new study by scientists from the Smithsonian, the Panamanian government, and the U.S. Environmental Protection Agency, among other institutions, concludes that conserving old-growth tropical rainforest is "highly recommended" to prevent new outbreaks of viral and parasitic mosquito-borne diseases.
Cardiovascular disease (CVD) is the leading cause of death in Europe, killing an estimated 4.3 million people each year. Results from a large pan-European study announced today indicate that many of these deaths could be avoided if at-risk patients received better preventative care.
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
Adolor Corporation today reported a net loss of $9.6 million, or $(0.21) per basic and diluted share, for the three months ended March 31, 2010, compared to a net loss of $13.2 million, or $(0.28) per basic and diluted share, for the three months ended March 31, 2009.
› Verified 5 days ago
Megan Dillon, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 4210 Lincoln Rd, Hattiesburg, MS 39402 Phone: 601-261-3500 Fax: 601-579-5240 | |
Lowry C Stanford Jr., MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 39 Franklin Rd, Ste 220, Hattiesburg, MS 39402 Phone: 601-296-3050 | |
Joshua Ryan Allen, Pediatrics Medicare: Medicare Enrolled Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 601-268-8000 | |
Damea B Benton, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 101 Medical Park, Hattiesburg, MS 39401 Phone: 601-579-3000 Fax: 601-579-5240 | |
Dr. Elizabeth M Felder, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 102 Medical Park, Hattiesburg, MS 39401 Phone: 601-261-5159 Fax: 601-545-1740 | |
Jeffrey C Williams, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 26 Deer Vly, Hattiesburg, MS 39402 Phone: 601-467-7336 | |
Dr. John Wells Gaudet, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 39 Franklin Rd, Ste. 200, Hattiesburg, MS 39402 Phone: 601-296-3050 Fax: 601-296-3013 |